

4th EQAsia Matrix EQA:

Selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing *Escherichia coli* from cultures mimicking meat samples – 2024

4th EQAsia Matrix EQA:

Selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing Escherichia coli from cultures mimicking meat samples - 2024

1st edition, March 2025

Report by:

DTU National Food Institute, Lyngby, Denmark:

Hiba Al Mir, Tomislav Kostyanev, Sarah Marvig Johansson, Elif Seyda Tosun,
Lone Brink Rasmussen and Rene S. Hendriksen

Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand:

Rangsiya Prathan, Patrarat Chanchaithong, Taradon Luangtongkum
and Rungtip Chuanchuen.

International Vaccine Institute, Seoul, South Korea:

Freshwork A. Abegaz, Tobin Guarnacci, Nimesh Poudyal and Soo-Young Kwon

Steering Committee Institutions:

World Health Organization

Food and Agriculture Organization of the United Nations

World Organisation for Animal Health

The Peter Doherty Institute for Infection and Immunity, Australia

Pacific Pathology Training Centre, New Zealand

NSW Health Pathology Microbiology, New South Wales, Australia

Copyright:

Full or partial reproduction of this publication is permitted
provided the source is acknowledged

Photo:

DTU National Food Institute

Published by:

DTU National Food Institute

Henrik Dams Allé

2800 Kgs. Lyngby

Denmark

ISBN:

978-87-7586-054-8

food.dtu.dk

Index

Executive Summary	3
1. Introduction	4
2. Materials and Methods	6
2.1 Participants in EQAsia Matrix EQA 2024	6
2.2 Samples preparation	6
2.3 Isolation and identification of ESBL-, AmpC- and carbapenemase-producing <i>E. coli</i>	7
2.4 Antimicrobials	8
2.5 Distribution	Error! Bookmark not defined.
2.6 Procedure	8
3. Results	9
3.1 Methods used by the participants	9
3.2 ESBL-, AmpC- and carbapenemase-producing <i>E. coli</i> isolation and identification	10
3.3 Antimicrobial Susceptibility Testing	12
3.4 ESBL, AmpC and carbapenemase phenotypic testing.....	15
3.5 Quality control strains	15
4. Discussion	17
5. Conclusion	18
6. References	19
7. Appendices	20
Appendix 1: Matrix EQA 2024 Protocol	20
Appendix 2: Reference values (MIC) – <i>Escherichia coli</i>	28
Appendix 3: Quality control ranges for reference strains	31

Executive Summary

This report summarizes the results of the 4th EQAsia Matrix EQA trial of the EQAsia project (Matrix EQA 2024), a Fleming Fund Regional Grant aiming to strengthen the provision of External Quality Assessment (EQA) services across the One Health sector among National Reference Laboratories / Centres of Excellence in South and Southeast Asia. EQAsia has been granted a 2nd phase (October 2023 to December 2025) to continue to deliver the established EQA for both the Human Health (HH sector) and Food and Animal Health (AH sector) laboratories in the region.

The trial was carried out in October-November 2024 and included isolation of *E. coli* presumptive of producing either ESBL, AmpC or carbapenemase enzymes from lyophilized cultures mimicking meat content, followed by antimicrobial susceptibility testing (AST) of the isolates.

A total of five HH and eight AH laboratories participated and submitted results for the Matrix

EQA. These laboratories are from five countries situated in South and Southeast Asia (Bangladesh, Nepal, Pakistan, Sri Lanka and Vietnam).

The participants used the recommended methods for selective isolation of the presumptive ESBL-, AmpC- or carbapenemase-producing *E. coli* isolates from the cultures mimicking meat content and applied biochemical tests for confirmation of the bacterial identification.

The four samples of presumptive ESBL-, AmpC- or carbapenemase-producing *E. coli* were correctly identified as positive by at least 90% of the laboratories.

All thirteen the participating laboratories submitted results for antimicrobial susceptibility testing and presented an average deviation of 11.3% (ranging from 4 to 21.4%) in terms of AST performance.

1. Introduction

The EQAsia project was launched in 2020 aiming to strengthen the provision of External Quality Assessment (EQA) services across the One Health sector among National Reference Laboratories / Centres of Excellence in South and Southeast Asia. EQAsia is supported by the Fleming Fund and strives to increase the quality of laboratory-based surveillance of WHO GLASS pathogens [1] and FAO priority pathogens [2]. EQAsia has been granted a 2nd phase to continue to deliver the established EQA for both the Human Health (HH) sector and the Food and Animal Health (AH) sector in the region from 2023 to 2025.

The EQAsia Consortium includes the National Food Institute, Technical University of Denmark (DTU Food) as the Lead Grantee, the International Vaccine Institute (IVI) in South Korea, and the Faculty of Veterinary Science, Chulalongkorn University (CUVET) in Thailand.

EQAsia provides a state-of-the-art EQA program free of charge for the South and Southeast Asian region through CUVET Thailand, an existing EQA provider in the region. The EQAsia program is designed to enable the laboratories to select and participate in relevant proficiency tests of both pathogen identification (ID) and antimicrobial susceptibility testing (AST), in line with the requirements of the WHO GLASS [1]. The EQA program is supported by an informatics module where laboratories can report their results and methods applied.

As suggested by FAO and in alignment with the scope of WHO Tricycle, the EQA trials taking place in 2021 have included a Matrix-based specific EQA in each year, aiming at assessing the laboratories' ability to detect and isolate AmpC beta-lactamases (AmpC), extended-spectrum beta-lactamases (ESBL) and carbapenemase-producing *Escherichia coli* from food matrices, followed by identification and antimicrobial susceptibility testing. The purpose of the Matrix EQA is to monitor the capacity of the participating laboratories to perform isolation

and AST of *E. coli* from food matrices and identify potential problems or focus areas for future training/education.

To prepare for the launch of the Matrix EQAs, several preliminary studies were conducted at CUVET Thailand, using meat samples spiked with *E. coli* isolates presumptive of producing either ESBL, AmpC or carbapenemase enzymes. However, due to the constraints in shipping such samples from Thailand to the participating countries, another approach was attempted. Shortly, a portion of pork-minced meat was spiked with an *E. coli* strain, the meat sample was pre-enriched and bacterial growth was allowed. The resulting bacterial culture (a mixture of the different bacteria present in the meat sample) was then lyophilized and a culture mimicking the meat content obtained (see section 2.2).

All *E. coli* isolates used for spiking the meat samples were assessed by DTU Food and the external partner (The Peter Doherty Institute for Infection and Immunity, Australia), and validated by CUVET Thailand. The assessment included both phenotypic minimum inhibitory concentration (MIC) determination by broth microdilution, and whole genome sequencing (WGS) to detect antimicrobial resistance (AMR) genes and chromosomal point mutations.

This report contains results from the 4th EQAsia Matrix EQA trial of the EQAsia project (Matrix EQA 2024) carried out in October-November 2024. The trial included a total of four lyophilized cultures mimicking meat content spiked with an *E. coli* isolate presumptive of producing either ESBL, AmpC or carbapenemase enzymes. For each of the four isolated *E. coli* strains, results in relation to AST and Selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing *Escherichia coli* were requested.

The evaluation of the participants' results is based on international guidelines, namely the Clinical and Laboratory Standards Institute

(CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Interpretative criteria referring to both disk diffusion and MIC determination are listed in the Matrix EQA protocol (**Appendix 1**) and allow for the obtained results to be interpreted into categories as resistant, intermediate, or susceptible depending on the method used. Results in agreement with the expected interpretation are scored '4' (correct), while results deviating from the expected interpretation are scored as either '0' (incorrect: very major), '1' (incorrect: major) or '3' (incorrect: minor), as explained in the Matrix EQA protocol (**Appendix 1**). This standardized interpretation of results is necessary to allow comparison of performance between laboratories. No thresholds were set in advance to evaluate the performance of the participating laboratories; thus, the results were evaluated case by case. Nevertheless, a laboratory performance of < 5% deviation from expected results would be considered ideal.

Evaluation of a result as “deviating from the expected interpretation” should be carefully analysed in a root cause analysis procedure performed by individual participants (self-evaluation) when the EQA results are disclosed. The methods applied have limitations in reproducibility, thus, on repeated testing, the same strain/antimicrobial combination can result in different MIC or inhibition zone diameter

values differing by one-fold dilution or ± 3 mm, respectively. If the expected MIC / zone diameter is close to the threshold for categorising the strain as susceptible or resistant, a one-fold dilution / ± 3 mm difference may result in different interpretations. As this report evaluates the interpretations of MIC / zone diameter and not the values, some participants may find their results classified as incorrect (score of 0, 1 or 3) even though the actual MIC / zone diameter measured is only one-fold dilution / ± 3 mm apart from the expected MIC / zone diameter. In these cases, the participants should be confident about the good quality of their AST performance.

In this report, results from laboratories affiliated with the HH or AH sectors are presented together. The laboratories are identified by codes and each code is known only by the corresponding laboratory and the organizers. The full list of laboratory codes is confidential and known only by the EQAsia Consortium.

This report is approved in its final version by a Technical Advisory Group composed by members of the EQAsia Consortium, and by the EQAsia Advisory Board members Ben Howden (The Peter Doherty Institute for Infection and Immunity, Australia), Monica Lahra (WHO Collaborating Centre for STI and AMR, NSW Health Pathology Microbiology, New South Wales, Australia) and Russel Cole (Pacific Pathology Training Centre, New Zealand).

2. Materials and Methods

2.1 Participants in EQAsia Matrix EQA 2024

A total of thirteen laboratories participated in the fourth EQAsia Matrix EQA trial of the EQAsia project: five laboratories belonging to the HH sector and eight belonging to the AH sector from Bangladesh, Nepal, Pakistan, Sri Lanka and Vietnam (**Figure 1**).

2.2 Samples preparation

Laboratories that registered for the Matrix EQA trial received four lyophilized cultures mimicking meat content for isolation of presumptive ESBL, AmpC- and carbapenemase-producing *E. coli*, including identification, and AST of the obtained isolates. The preparation of the cultures followed the official [EURL-AR protocols](#) [3]. The pre-testing and spiking of the meat samples are briefly described below:

Pre-testing

Firstly, pork minced meat samples were tested for the presence of ESBL-, AmpC-, and carbapenemase-producing *E. coli* to ensure that the meat does not naturally contain these type of

bacteria. Meat portions of 25 g were mixed with 225 mL of buffered peptone water (BPW) and incubated at 37°C ± 1°C for 18-22 h (pre-enrichment step as referred to in the [EURL-AR protocols](#)). A loopful of the pre-enriched culture was plated onto a MacConkey agar plate containing 1 mg/L of cefotaxime and incubated overnight to assure that the batch used was negative for ESBL/AmpC/carbapenemase-producing *E. coli* and that it contained some background flora.

Spiking of the meat samples

To prepare the four lyophilized cultures mimicking meat content, four 25 g pork minced meat portions from the same batch as in the pre-testing were used, and all the portions were spiked with an *E. coli* isolate.

After spiking the meat with the *E. coli* isolates, all meat portions were mixed with BPW, incubated, and plated on selective agar as described in the pre-testing. The grown colonies, consisting in a mixture of the different bacteria present in the meat sample were then scrapped and lyophilized.



Figure 1: Countries participating in the 4th EQAsia Matrix EQA 2024. Color indicates sector affiliation of the participating laboratory as Animal Health laboratory (yellow), Human Health laboratory (blue) or both Human and Animal Health laboratories (green). Created with MapChart.net.

2.3 Isolation and identification of ESBL-, AmpC- and carbapenemase-producing *E. coli*

The *E. coli* isolates used for this EQA were tested at DTU Food and by the external partner (The Peter Doherty Institute for Infection and Immunity, Australia), and additionally verified by CUVET Thailand. Expected MIC values can be found in **Appendix 2**. The reference strains *E. coli* ATCC 25922 and *E. coli* NCTC 13846 were supplied during previous EQA rounds to participants free of charge with instructions for storage and maintenance for quality assurance purposes and future EQA trials. The expected quality control ranges for the reference strain *E. coli* ATCC 25922 were retrieved from Clinical and Laboratory Standards Institute (CLSI) in document M100-34th Ed. [4], tables 4A-1 and 5A-1, and for *E. coli* NCTC 13846 from EUCAST in document "Routine and extended internal quality

control for MIC determination and disk diffusion" [5] (**Appendix 3**).

The protocols for selective isolation and identification of the ESBL-, AmpC- and carbapenemase-producing *E. coli* isolates contained in the lyophilized cultures were briefly described in the Matrix EQA protocol (**Appendix 1**) and are based on the official [EURL-AR protocols](#) [3]. For bacterial identification, the participants were asked to perform the methods routinely applied in their laboratories. Information about the methods used for selective isolation and species identification were requested when submitting results in the informatics module.

2.4 Antimicrobials

The antimicrobials recommended for AST in this trial are listed in the protocol (**Appendix 1**) and summarized in **Table 1**. These antimicrobials

correspond to several antimicrobial class representatives important for surveillance, as well as antimicrobials required for detection and confirmation of ESBL-, AmpC- and carbapenemase-producing phenotypes.

The reference values used in this EQA for interpreting MIC and disk diffusion results are in accordance with current zone diameter and MIC breakpoint values developed by CLSI (M100, 34th Ed.) [4]. When not available, EUCAST clinical breakpoints (Tables v. 13.0, 2023) [5] or epidemiological cut off values [6] were used instead. Cefotaxime/ clavulanic acid and ceftazidime/ clavulanic acid results were not scored, as these drug combinations are mostly important for confirmation of ESBL-, AmpC- and carbapenemase-producing phenotypes. Results for presumptive beta-lactam resistance mechanisms were interpreted according to the most recent EFSA (European Food Safety Authority) [7] recommendations also included in the Matrix EQA protocol (**Appendix 1**).

Participants were encouraged to test as many as possible of the antimicrobials listed, but always considering their relevance regarding the laboratory's routine work.

2.5 Distribution

CUVET Thailand dispatched the lyophilized cultures in October 2024 to all participating laboratories. The shipment (UN3373, biological substances category B) was done according to International Air Transport Association (IATA) regulations. Participating laboratories received information on how to open, revive and store these lyophilized cultures.

Table 1. Panel of antimicrobials and respective abbreviations for AST of *E. coli* included in the EQAsia Matrix EQA 2024. For the antimicrobials in grey, no interpretative criteria were available and/or scored in the informatics module.

Antimicrobials – *E. coli* AST

Amikacin (AMK)
Ampicillin (AMP)
Azithromycin (AZI)
Cefepime (FEP)
Cefotaxime (FOT)
Cefotaxime/clavulanic acid (F/C)
Cefoxitin (FOX)
Ceftazidime (TAZ)
Ceftazidime/clavulanic acid (T/C)
Chloramphenicol (CHL)
Ciprofloxacin (CIP)
Colistin (COL)
Doripenem (DOR)
Ertapenem (ETP)
Gentamicin (GEN)
Imipenem (IMI)
Levofloxacin (LEVO)
Meropenem (MERO)
Nalidixic Acid (NAL)
Piperacillin/tazobactam (P/T4)
Sulfamethoxazole (SMX)
Tetracycline (TET)
Tigecycline (TGC)
Tobramycin (TOB)
Trimethoprim (TMP)
Trimethoprim/sulfamethoxazole (SXT)

2.6 Procedure

Protocols and all relevant information were available at the EQAsia website [8], and accessible at any time throughout the EQA trial. The participants were recommended to store the lyophilized samples in a dark, dry, and cool place until performing selective isolation and AST.

Participating laboratories were advised to perform identification and AST of the test strains according to the methods routinely applied in their laboratory.

Procedures such as disk diffusion, gradient test, agar dilution and broth dilution were acceptable. For the interpretation of results, only the categorisation as resistant / intermediate / susceptible (R/I/S) was evaluated, whereas MIC and inhibition zone diameter values were used as supplementary information.

All participants were invited to enter the obtained results into an informatics module designed for this trial. The informatics module could be accessed through a secured individual login and

password. After release of the results, the participants were invited to login to retrieve an

individual database-generated evaluation report.

3. Results

3.1 Methods used by the participants

Participants were asked to indicate the methods used for selective isolation of the *E. coli* strains, as well as the method used for bacterial identification, during results submission in the informatics module. **Figure 2** summarizes the methods reported by the participants.

Ten of the thirteen participating laboratories (#01, #14, #22, #33, #34, #37, #40, #46, #55 and #69) reported that selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing *E. coli* was performed exactly according to the protocol provided in the Matrix EQA protocol (**Appendix 1**), which is based in the official [EURL-AR protocols](#) [3], meaning that no changes in media, concentrations of antibiotics, etc. were referred

(**Figure 2**, left column). Laboratories #12, #41 and #67 reported that the protocol was used, but the selective isolation procedures were modified.

Regarding selective isolation of carbapenemase-producers (**Figure 2**, middle column), laboratories #01, #12, #14, #22, #33, #34, #40, #41, #46, #55, #67 and #69 reported that carbapenemase selective isolation was not performed, whereas laboratory #37 reported that carbapenemase selective isolation was performed.

Confirmation of *E. coli* species identification (**Figure 2**, right column) was performed by laboratories #01, #12, #22, #40, #41, #46, #55 and #55 using biochemical tests. Laboratories #34, #37 and #67 used chromogenic media while laboratory #14 and #69 conducted MALDI-ToF. Only laboratory #33 conducted PCR using published methods.




Figure 2. Methods used by the participants for selective isolation and confirmation of *E. coli* species identification.

3.2 ESBL-, AmpC- and carbapenemase-producing *E. coli* isolation and identification

Samples EQAsia 24.M1, EQAsia 24.M2, EQAsia 24.M3 and EQAsia 24.M4 were spiked with different *E. coli* isolates and, therefore, expected to be positive for growth of presumptive ESBL-, AmpC- or carbapenemase-producing *E. coli*. Participants were asked to describe the growth

observed in the selective plates (**Table 2**).

For samples EQAsia 24.M1, 23.1% of the laboratories, described the presence of typical *E. coli* colonies as a pure culture. In contrast, for samples EQAsia 24.M2 and EQAsia 24.M3, this percentage increased to 38.5%. For sample EQAsia 24.M4, only one of the laboratories reported the absence of typical *E. coli* colonies respectively (**Table 2**).

Table 2. Expected and obtained results for ESBL/AmpC/carbapenemase-producing *E. coli* isolation. Number of obtained results (n) out of the total of reported results (N) is presented for each growth type and for each sample, as well as for the species identification. Obtained results in accordance with the expected result are shown in bold.

Growth observed on the selective plates	EQAsia 24.M1	EQAsia 24.M2	EQAsia 24.M3	EQAsia 24.M4
Mixed culture containing typical <i>E. coli</i> colonies	7/13 (53.8%)	8/13 (61.5%)	8/13 (61.5%)	8/13 (61.5%)
Mixed culture without typical <i>E. coli</i> colonies	--	--	--	1/13 (7.7%)
Pure culture of typical <i>E. coli</i> colonies	3/13 (23.1%)	5/13 (38.5%)	5/13 (38.5%)	4/13 (30.8%)
Pure culture without typical <i>E. coli</i> colonies	--	--	--	--
No growth	3/13 (23.1%)	--	--	--

(n/N) number of responses (n) out of the total of reported results (N)

Results confirming the species identification were reported by all laboratories (**Table 3**):

- EQAsia 24.M1: sample was confirmed as positive by ten laboratories (#012, #14, #22, #33, #37, #40, #41, #46, #55 and #67) where laboratories (#37, #40 and #55) have reported it as a pure culture of typical *E. coli* colonies. Laboratory #12, #14, #22, #33, #41, #46 and #67 however, reported it as mixed culture containing typical *E. coli* colonies. Laboratories #37, #40 and #55, which observed no growth reported the sample as negative.
- EQAsia 24.M2: sample was confirmed as positive by all thirteen laboratories whereas laboratories (#12, #14, #22, #33, #34 and #67) have reported it as a pure culture of typical *E. coli* colonies. Laboratories #01, #37, #40, #41, #55 and #69 have reported it as mixed culture containing typical *E. coli* colonies.
- EQAsia 24.M3: sample was confirmed as positive by all thirteen laboratories whereas eight laboratories (#12, #14, #22, #33, #34, #41, #46 and #67) have

reported it as a pure culture of typical *E. coli* colonies. Five laboratories (#01, #37, #40, #55 and #69) have reported it as mixed culture containing typical *E. coli* colonies.

- EQAsia 24.M4: sample was confirmed as positive by twelve laboratories whereas eight laboratories (#12, #14, #22, #33, #34, #37, #41 and #46) have reported it as a pure culture of typical *E. coli* colonies. Laboratories (#01, #40, #55 and #69) have reported it as mixed culture containing typical *E. coli* colonies. However, laboratory #67 which observed 'Mixed culture without typical *E. coli* colonies' reported it as negative.

In summary (**Table 3**), eight laboratories (#12, #14, #22, #33, #37, #40, #46 and #55) reported all samples as positive for presumptive ESBL-, AmpC- or carbapenemase-producing *E. coli*. Two Laboratories (#40 and #55) correctly reported all four samples as positive pure culture of typical *E. coli*.

Table 3. Obtained results for ESBL/AmpC/carbapenemase-producing *E. coli* species identification reported by each laboratory for each sample. Presumptive ESBL/AmpC/carbapenemase isolates identified as *E. coli* are presented as 'Positive', and not *E. coli* or not tested samples are presented as 'Negative'. Obtained results in accordance with the expected result are shown in bold.

Laboratory ID Number	EQAsia 24.M1	EQAsia 24.M2	EQAsia 24.M3	EQAsia 24.M4
#01	Negative	Positive	Positive	Positive
#12	Positive	Positive	Positive	Positive
#14	Positive	Positive	Positive	Positive
#22	Positive	Positive	Positive	Positive
#33	Positive	Positive	Positive	Positive
#34	Negative	Positive	Positive	Positive
#37	Positive	Positive	Positive	Positive
#40	Positive	Positive	Positive	Positive
#41	Positive	Negative	Positive	Positive
#46	Positive	Positive	Positive	Positive
#55	Positive	Positive	Positive	Positive
#67	Positive	Positive	Positive	Negative

#69

Negative

Positive

Positive

Positive

3.3 Antimicrobial Susceptibility Testing

For all samples considered positive for ESBL-, AmpC- or carbapenemase-producing *E. coli*, one *E. coli* isolate per sample should be taken and further tested for susceptibility towards the antimicrobials suggested in the Matrix EQA protocol (**Appendix 1**) and outlined in **Table 1**.

All thirteen laboratories submitted results for AST. For sample EQAsia 24.M1 and its respective *E. coli* isolates, results were only available from ten laboratories, since laboratories #01, #34 and #69 considered the sample negative. For sample EQAsia 24.M4 and its respective *E. coli* isolates, laboratory #69 reported the sample as negative and did not submit AST results. Laboratory #41 also submitted AST results for sample EQAsia 24.M2 despite reporting it as non Presumptive ESBL/AmpC isolate.

The participants were invited to report inhibition zone diameters/MIC values and categorization as resistant ('R'), intermediate ('I') or susceptible ('S') for each strain/antimicrobial combination. Only the categorization was evaluated, whereas the inhibition zone diameters/MIC values were used as supplementary information.

The Matrix EQA set-up allowed laboratories to choose the antimicrobials to be tested among the panel of suggested antimicrobials (**Table 1**). Twelve participating laboratories applied disk diffusion for testing the antimicrobials and, therefore, reported inhibition zone diameters (**Table 4**). Laboratories #12, #14 and #37 reported performing MIC – broth microdilution for several antimicrobials. Antimicrobials such as ampicillin, cefoxitin, ceftazidime and gentamicin were tested by all thirteen laboratories. Sulfamethoxazole was tested by only two laboratories (#46 and #69). Colistin was exclusively tested by three laboratories #12, #14 and #37 for all samples using MIC-broth microdilution method. Other laboratories did not

conduct this test as their chosen methodology is not suitable for testing this drug.

Table 4. Antimicrobial agents tested by the laboratories and by method applied. The number of participating laboratories that tested each antimicrobial is shown (n), as well as the percentage (%) of laboratories out of the total number of participating laboratories (N) for the trial (% of n/N).

Antimicrobial	Laboratories in total: n (% of n/N)	Laboratories in total: n (% of n/N)
	Disk Diffusion	MIC
AMK	12 (92.3)	--
AMP	12 (92.3)	1 (7.7)
AZI	8 (61.5)	--
FEP	6 (46.2)	1 (7.7)
FOT	12 (92.3)	1 (7.7)
FOX	13 (100.0)	--
TAZ	13 (100.0)	--
CHL	12 (92.3)	--
CIP	12 (92.3)	--
COL	--	3 (23.1)
DOR	5 (38.5)	--
ETP	6 (46.2)	1 (7.7)
GEN	12 (92.3)	1 (7.7)
IMI	10 (76.9)	1 (7.7)
LEVO	6 (46.2)	1 (7.7)
MERO	11 (84.6)	1 (7.7)
NAL	11 (84.6)	--
PT4	7 (53.8)	1 (7.7)
SMX	2 (15.4)	--
TET	11 (84.6)	--
TGC	4 (30.8)	2 (15.4)
TOB	3 (23.1)	--
TMP	6 (46.2)	--
SXT	12 (92.3)	1 (7.7)
Total	13	--

Disk Diffusion – inhibition zone diameter determination by disk diffusion

The AST performance of the laboratories can be analysed from a strain-, antimicrobial-, and laboratory-based perspective. From a strain-analysis point of view (**Figure 3**), the *E. coli* strain used to spike sample EQAsia 24.M4 presented the lowest deviation (3.9%), meaning that most of the susceptibility results obtained were in accordance with the expected (**Appendix 2**). The other three samples revealed more than 5% deviation, where the highest deviation (26%) was observed for the *E. coli*

strain isolated from EQAsia 24.M2.




Figure 3. Percentage of deviation in the AST interpretation (R/I/S) per sample in the EQAsia Matrix EQA 2024.

Antimicrobials with highest deviations from the expected result were ceftazidime (27.7%), as well as levofloxacin (24%), whereas ampicillin,

sulfamethoxazole, tigecycline, tobramycin and trimethoprim revealed no deviation from the expected results and doripenem and meropenem had a deviation of less than 5% (**Figure 4**).

Ceftazidime was tested by all laboratories for samples EQAsia 24.M2, EQAsia 24.M3 and EQAsia 24.M4. Laboratories #34 and #69 did not perform the test for sample EQAsia 24.M1. Some of the strains expected to be susceptible to the drug were reported as intermediate or resistant leading to the score penalties (score of 0 and 3 instead of 4) that contributed to the observed deviation.

The deviation observed in levofloxacin testing was caused by an incorrect result, but that was a very major error, such as reporting a resistant strain as susceptible or a susceptible strain as resistant.




Figure 4. Percentage of deviation in the AST interpretation (R/I/S) among the *E. coli* strains used to spike the matrix samples in EQAsia Matrix EQA 2024. Results are categorized according to antimicrobial agent. Bars represent the average distribution of the deviation.

A deviation below 5% of laboratory performance in terms of interpretation of the results (R/I/S) was observed for laboratory #37 (EQAsia 24.M2) for doripenem and #12 (EQAsia 24.M3) for meropenem (**Figure 5**). In average, the deviation

was 11.3% (ranging from 4.0 to 21.4%).

Laboratory #33' deviations were mostly caused by major errors, in particular for the strain used to spike samples EQAsia 24.M1 and EQAsia 24.M2.

Laboratory #12' deviations were mainly attributed to major errors for antimicrobials such as cefepime, ceftazidime, and ciprofloxacin.

Laboratory #34 presented several deviations from the expected results, notably regarding the strain used to spike sample EQAsia 24.M2 as mentioned above.

Laboratory #22' deviations were due to major

errors in testing amikacin, ceftazidime and Piperacillin/tazobactam, while laboratory #46 showed several deviations caused by minor errors. In this case, some strains expected to be susceptible to the drug were reported as intermediate.




Figure 5. Percentage of deviation in the AST interpretation (R/I/S) among the *E. coli* strains used to spike the matrix samples in EQAsia Matrix EQA 2024. Results are categorized by laboratory ID number.

3.4 ESBL, AmpC and Carbapenemase phenotypic testing

Four lyophilized samples mimicking meat content were included in this Matrix EQA. The sample EQAsia 24.M1 contained an *E. coli* isolate expressing ESBL-producer phenotype (**Table 5**). Eight of the participating laboratories correctly classified the phenotype (#14, #22, #33, #37, #40, #41, #55 and #67), Whereas laboratory #46 classified the strain as ESBL+AmpC producer as they observed synergy and reported the strain resistant to ceftazidime.

The *E. coli* isolate from sample EQAsia 24.M4 had an AmpC-producer phenotype (**Table 5**). Nine of the laboratories reported the correct phenotype (#01, #12, #14, #22, #34, #40, #41, #46 and #55), whereas laboratories #33 and #37

classified the strain as an ESBL+AmpC producer even though neither ceftazidime nor ceftazidime in combination with clavulanic acid were tested and, therefore, synergy could not be observed.

Sample EQAsia 24.M3 was spiked with an *E. coli* isolate with a carbapenemase-producer phenotype (**Table 5**). Nine of the laboratories reported the correct phenotype (#01, #14, #22, #34, #37, #40, #41, #67 and #69) whereas laboratories #33 and #46 reported it as an ESBL+AmpC-producer (synergy observed and sample reported as resistant to ceftazidime and susceptible to meropenem). Laboratory #55 classified the sample as “other phenotype” reporting resistance to ceftazidime, no synergy observed and meropenem not tested.

Lastly, the *E. coli* isolate from sample EQAsia 24.M2 had an ESBL+AmpC producer phenotype (**Table 5**), which was not correctly identified by any of laboratories submitting results. Seven

laboratories (#22, #33, 37, #40, #55, #67 and #69) reported the sample as an ESBL-producer and laboratory #46 classified it as AmpC producer.

In summary, laboratories #14, #22, #40 and #41

presented one incorrect classification of the different ESBL / AmpC / carbapenemase phenotypes among the four *E. coli* strains and laboratories #01 and #34 correctly identified the phenotypes for all the strains assessed.

Table 5. Expected and obtained classification of ESBL-, AmpC- and carbapenemase-producing *E. coli* strains used to spike the matrix samples. Number of obtained results (n) out of the total of reported results (N) is presented for each phenotype and for each strain. Obtained results in accordance with the expected result are shown in bold.

Sample ID	EQAsia 24.M1	EQAsia 24.M2	EQAsia 24.M3	EQAsia 24.M4
Expected results	ESBL	ESBL+AmpC	Carbapenemase	AmpC
Obtained results (n/N)	ESBL	8/9 (88.9%)	7/8 (87.5%)	--
	AmpC	--	1/8 (12.5%)	9/12 (75%)
	ESBL + AmpC	1/9 (11.1%)	--	2/12 (16.7%)
	Carbapenemase	--	--	9/12 (75%)
	Other phenotypes	--	--	1/12 (8.3%)
	Susceptible*	--	--	--

*no AmpC, ESBL and Carbapenemase;

(n/N) number of responses (n) out of the total of reported results (N)

3.5 Quality control strains

The quality control strains *E. coli* ATCC 25922 and *E. coli* NCTC 13846 (for colistin) were sent free of charge to participating laboratories in previous trials to be used as reference strains.

Antimicrobial susceptibility test results for the quality control strain *E. coli* ATCC 25922 were submitted by twelve of the participating laboratories, where only lab #41 did not submit any results. Laboratories applied the disk diffusion method and reported inhibition zone diameters. Laboratories #12 and #14 reported using MIC- broth microdilution for a number of antimicrobials. As colistin should not be tested by disk diffusion, very few results were submitted for this drug and, therefore, the quality control strain *E. coli* NCTC 13846 was tested by laboratories #14 and #37.

The highest proportion of test results outside of the expected range were observed for ertapenem (4 out of 7), doripenem (2 out of 5) and cefepime (2 out of 6) whereas no deviations were observed for colistin, levofloxacin,

tobramycin and trimethoprim (**Table 6**).

These incorrect results led to the laboratories' deviation summarized in **Figure 6**. Laboratories #01, #34 and #67 presented no deviation. Inversely, laboratory #55 deviation was as high as 54.5%.

Table 6. AST of the reference strain *E. coli* ATCC 25922. Proportion of test results outside of expected range is presented by methodology used.

Antimicrobial	Proportion outside of range	
	Disk Diffusion	
AMK	1/11	
AMP	3/12	
FEP	2/6	
FOT	2/12	
FOX	1/12	
TAZ	1/12	
CHL	3/11	
CIP	2/12	
DOR	2/5	
ETP	4/7	
GEN	1/12	
IMI	2/10	
LEVO	0/6	

MERO	2/11
NAL	1/10
PT4	1/8
SMX	2/2
TET	2/9
TGC	1/6
TOB	0/3
TMP	0/5
SXT	3/10

Disk Diffusion – inhibition zone diameter determination by disk diffusion

Laboratory #55 obtained 6 out of 11 results outside of range. Specifically, results for cefotaxime and ceftazidime were just slightly (1 mm) below the acceptance interval, whereas results for ampicillin, chloramphenicol, gentamicin, nalidixic acid, tetracycline, trimethoprim/sulfamethoxazole were above (2, 2, 2, 2, 3 and 7 mm, respectively) the accepted range. A similar finding is observed for laboratory #46, whereas 9 out of 15 test results were outside of range. Result for sulfamethoxazole was 1 mm above the acceptance interval, whereas results for amikacin, cefepime, ceftazidime, chloramphenicol, ciprofloxacin,

ertapenem, and meropenem were below (2, 5, 4, 3, 2, 19, and 5 mm respectively) the accepted range.

Laboratory #37 reported inhibition zone diameters for ampicillin, cefepime, doripenem, ertapenem, imipenem and meropenem below (more than 3 mm, respectively) the acceptance interval, and laboratory #40 reported results for cefotaxime, chloramphenicol, imipenem and trimethoprim/sulfamethoxazole above (1, 3, 1 and 3 mm, respectively) the expected range.




Figure 6. Percentage of deviation in the AST of the quality control strain *E. coli* ATCC 25922 by the laboratories.

4. Discussion

A total of thirteen laboratories from both the HH and AH sectors participated in the 4th EQAsia Matrix EQA on selective isolation of presumptive ESBL- AmpC- and carbapenemase-producing *E. coli* from cultures mimicking meat samples. In general, the participants used the recommended methods for selective isolation, which are based on the official [EURL-AR protocols](#) [3]. Only one of the participating laboratories performed carbapenemase selective isolation using specific selective plates. Bacterial identification was achieved using biochemical tests, chromogenic media, MALDI-ToF and PCR using published methods.

All samples EQAsia 24.M1, EQAsia 24.M2, EQAsia 24.M3 and EQAsia 24.M4 were expected to be positive for growth of presumptive ESBL-, AmpC- or carbapenemase-producing *E. coli*. Regarding the positive samples, at least 61.5% of the laboratories correctly identified the samples as positive for the presence of *E. coli* colonies. Sample EQAsia 24.M1 seemed to cause more problems as several laboratories (3 out of 13) reported the sample as negative instead of positive, which demonstrates the need for more education and training in the selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing bacteria from complex matrices.

All thirteen participating laboratories submitted results for antimicrobial susceptibility testing. The AST performance was assessed from different perspectives to better identify deviations from the expected results. Hence, the strain-based analysis revealed that the *E. coli* strain isolated from sample EQAsia 24.M2 presented the highest deviation from the expected results in comparison to the other three isolates. One possible explanation could be the ESBL-AmpC phenotype of the strain. high level of resistance of this strain towards cefotaxime (MIC > 32), which assured the growth of this

strain on the selective MacConkey agar plate containing 1 mg/L cefotaxime. The other isolates, which are less resistant to cefotaxime (**Appendix 2**) may be overgrown by contaminating bacteria and more challenging to isolate. Nevertheless, it is not completely clear if the submitted results for the remaining *E. coli* strains are due to the isolation and testing of other bacteria than the target one used to spike the samples with. Therefore, the possibility of performance issues cannot be discarded.

The several incorrect results observed for sample EQAsia 24.M2 were the main contributor for the highest deviation in terms of laboratories' AST performance, which presented an average deviation of 11.1% (ranging from 3.9 to 26%). However, this represents an improvement compared to the deviations observed in the previous Matrix EQA 2023, indicating progress in overall testing accuracy.

A few incorrect results were reported by the laboratories for the classification of the *E. coli* phenotypes into ESBL, AmpC or carbapenemase-producers. These seem to have been caused by the incorrect results obtained for relevant antimicrobials, rather than by incorrect classification. Unlike the previous Matrix EQA 2023, no laboratory incorrectly classified any strains as carbapenemase-producing in this round. This reflects an improvement in testing accuracy, reducing the risk of misclassification and ensuring reliable antimicrobial susceptibility results.

Lastly, regarding AST of the quality control strains, the majority of the results outside the quality control range were (2-4 mm) below/above the acceptance interval. It demonstrates possible technical problems in performing AST but may also suggest problems in maintenance of the quality control strains.

5. Conclusion

This report presented the results of the third EQAsia Matrix EQA trial 2024. This EQA assessed the performance in 1) isolation and identification of presumptive ESBL-, AmpC-, and carbapenemase-producing *E. coli* from cultures mimicking meat content, 2) AST determination and interpretation and 3) detection and classification of β -lactam resistance phenotypes mediated by ESBL, AmpC and carbapenemase enzymes.

The goal of the EQAsia Matrix EQAs is to ensure that all participating Human and Animal Health laboratories are able to provide quality data to be used for the comparability of surveillance data on ESBL-, AmpC- or carbapenemase-producing *E. coli* reported by different laboratories.

This Matrix EQA trial allowed the EQAsia Consortium to have once again an overview of the laboratories' capacity for a complete participation in such a proficiency test. Firstly, only thirteen laboratories participated in the trial, even though 17 laboratories initially signed up for it. The reason for not participating was mainly the lack of essential resources, such as selective media/plates. Secondly, it seems that the

laboratories can classify the resistance phenotypes, however incorrect results obtained for certain antimicrobials will lead to incorrect classification. Lastly, some laboratories may lack resources required for this type of proficiency test, such as cefotaxime/clavulanic acid or ceftazidime/clavulanic acid combination required for confirmatory testing.

On a final note, even though this trial was initially meant for laboratories of the Animal Health sector, since ESBL-, AmpC- and carbapenemase-producing *E. coli* continue to spread in food-producing animals, we were pleased to see the interest from the Human Health laboratories in participating, aligned with the concept of the WHO, FAO, WOHA tripartite Tricycle project. In fact, the increasing number of this type of strains is concerning and it is of high importance to support all type of laboratories with technical guidance and capacity building. In future EQAs, the EQAsia Consortium will aim at providing samples from other complex matrices that could be more relevant for the Human Health Sector.

6. References

- [1] Annex 8: Pathogen-antimicrobial combinations under GLASS-AMR surveillance. Global antimicrobial resistance and use surveillance system (GLASS) report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
- [2] FAO. 2019. Monitoring and surveillance of antimicrobial resistance in bacteria from healthy food animals intended for consumption. Regional Antimicrobial Resistance Monitoring and Surveillance Guidelines – Volume 1. Bangkok.
- [3] EURL-AR protocols: <https://www.eurl-ar.eu/protocols.aspx>
- [4] CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 34th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2024.
- [5] The European Committee on Antimicrobial Susceptibility Testing. *Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST*. Version 13.0, 2023.
- [6] EUCAST Website: <https://www.eucast.org/>
- [7] EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2020. The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2017/2018.
- [8] EQAsia Website: <https://antimicrobialresistance.dk/eqasia.aspx>

7. Appendices

Appendix 1: Matrix EQA 2024 Protocol



EQAsia Matrix EQA 2024

Protocol

Selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing *Escherichia coli* from cultures mimicking meat samples

1	INTRODUCTION	2
2	OBJECTIVES	2
3	OUTLINE OF THE MATRIX EQA 2024	3
	3.1 Shipping and receipt of strains	3
	3.2 Reviving and storage of strains.....	4
	3.3 Selective isolation of ESBL, AmpC or carbapenemase-producing <i>E. coli</i> from the samples.....	5
	3.4 Antimicrobial susceptibility testing	7
4	SUBMISSION OF RESULTS VIA THE INFORMATICS MODULE	12
5	EVALUATION OF RESULTS.....	13
	APPENDIX 1	14



1 INTRODUCTION

The EQAsia project aims to strengthen the provision of External Quality Assessment (EQA) services across the **One Health** sector in South and Southeast Asia. Therefore, a comprehensive and high-quality EQA program for antimicrobial resistance (AMR) is offered to all the National Reference Laboratories/Centres of Excellence in the region since 2021. The EQA is organized by the EQAsia consortium and supported by the Fleming Fund.

Aligning with the scope of WHO Tricycle and as suggested by FAO, the EQAsia EQA9 2024 includes a **Matrix EQA** aiming at assessing the laboratories' ability to detect AmpC beta-lactamases (AmpC), extended-spectrum beta-lactamases (ESBL) and carbapenemase-producing *Escherichia coli* from food matrices.

The **Matrix EQA 2024** therefore entails the selective isolation of ESBL-, AmpC- and carbapenemase-producing *E. coli*, as well as antimicrobial susceptibility testing (AST) of obtained isolates from four cultures mimicking meat content. These samples consist of four lyophilized bacterial cultures obtained from 25g samples of minced pork meat. Briefly, 25g of minced pork meat were spiked with an *E. coli* strain. The meat sample was then pre-enriched by the addition of 225 ml of Buffered Peptone Water (BPW, **Appendix 1**) and incubated at $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$ for 18-22 h (pre-enrichment step as referred in the official [EURL-AR protocols](#)). A loopfull of the pre-enriched culture was plated and incubated overnight. The grown cells (a mixture of the different bacteria present in the meat sample) were then scrapped and a lyophilized culture prepared. These lyophilized cultures contain *E. coli* that may be producing ESBL-, AmpC- or carbapenemase-enzymes.

The procedures described here, on how to perform the selective bacterial isolation, follow the EU recommended methods published on the [EURL-AR website](#).

Additionally, antimicrobial susceptibility testing of the reference strains *Escherichia coli* ATCC 25922/CCM 3954 and *E. coli* NCTC 13846/CCM 8874 (for colistin) for quality control (QC) in relation to antimicrobial susceptibility testing is included. These reference strains are original CERTIFIED cultures provided free of charge in previous EQAsia EQAs and should be stored for future internal quality control for antimicrobial susceptibility testing in your laboratory. Therefore, please take proper care of these strains. Handle and maintain them as suggested in the manual '[Subculture and maintenance of quality control strains](#)' available on the [EQAsia website](#).

2 OBJECTIVES

The main objective of the Matrix EQA is to support laboratories to assess and if necessary, improve the quality of results obtained in the selective isolation of presumptive ESBL-, AmpC- or carbapenemase-producing isolates from mixed samples. A further objective is to assess and improve the comparability of surveillance data on ESBL-, AmpC- or carbapenemase-producing *E. coli* reported by different laboratories. Therefore, the laboratory work for the Matrix EQA should be performed using the methods routinely applied in your laboratory. Additional methodology for selective isolation is provided in section 3.2.



3 OUTLINE OF THE MATRIX EQA 2024

3.1 Shipping and receipt of strains

In October 2024, participating laboratories located in South and Southeast Asia will receive a parcel containing four lyophilized cultures obtained from meat samples. The lyophilized cultures obtained from spiked matrix samples of pork meat content will be distributed in separate vials labelled as EQAsia 24.M1 to M4. Participants should expect that ESBL-, AmpC- and/or carbapenemase-enzymes producing *E. coli* strains will be included in some of the lyophilized cultures.

Please confirm receipt of the parcel through the confirmation form enclosed in the shipment

All strains used in the spiking of samples are categorised as UN3373, Biological substance, category B. These strains can potentially be harmful to humans and pose a risk due to their possible pan-resistant profile, therefore becoming a challenge in the treatment of a potential human infection. It is the recipient laboratory's responsibility to comply with national legislation, rules and regulations regarding the correct use and handling of the provided test strains, and to possess the proper equipment and protocols to handle these strains. Nevertheless, it is recommended to handle the strains in a BSL2 containment facility using equipment and operational practices for work involving infectious or potentially infectious materials. The containment and operational requirements may vary with the species, subspecies, and/or strains, thus, please take the necessary precautions.

Please consult the [Pathogen Safety Data Sheets](#) (PSDSs) produced by the Public Health Agency of Canada. The PSDSs of each pathogen can be found in the bottom of the page. These PSDSs are technical documents that describe the hazardous properties of human pathogens, and provide recommendations for the work involving these agents in a laboratory setting.

3.2 Reviving and storage of strains

Upon arrival, the lyophilized cultures must be stored in a dark, dry and cool place until microbiological analysis. This should be initiated as soon as possible after receipt in the laboratory.

Testing of meat samples requires a pre-enrichment step as referred in the official [EURL-AR protocols](#). As the provided samples are lyophilized cultures mimicking meat content, no pre-enrichment step is required (it has already been done prior to shipping the samples). Instead, the lyophilized cultures should be revived before proceeding to the selective isolation.

Aseptic technique must be applied throughout. All testing should be performed in a BSL2 level laboratory or in a biosafety cabinet class II.

- Needed material:
 - An ampoule cutter or a file
 - Sterile Luria Bertani (LB) broth
 - Agar plates (5 to 6 plates per one strain)
 - Autopipette with tips or Pasteur pipettes
 - Inoculating loop

1. Carefully take the ampoule out of the wrap.


Note: To maintain the vacuum condition, do not break the tip of the ampoule. Otherwise, the air will enter the ampoule and the cotton wool plug will be pushed down and in contact with dried bacterial culture. If it happens, please simply remove the cotton plug with forceps.

Note: The ampoule can be cut in the middle or below the cotton wool plug.

2. Wipe the ampoule neck with 70% alcohol-dampened cotton wool.




3. Make a deep score on the around the circumference of the ampoule near the middle of the plug using ampoule cutter or a file. The ampoule should be cut in the middle or below the cotton wool plug.



4. Wrap thick cotton wool around the ampoule and break at the marked area.

5. Remove the pointed end of the ampoule and cotton into a biohazard container. Add 0.5 mL of sterile LB broth into the lyophilized cells. Mix gently and carefully to avoid creating aerosols.



6. Then, transfer all re-suspended cells into 5mL fresh LB broth.

3.3 Selective isolation of ESBL, AmpC or carbapenemase-producing *E. coli* from the samples

7. After mixing gently the culture, subculture one loopful (10 μ L loop) by applying a single streak onto a MacConkey agar plate containing 1 mg/L of cefotaxime (**Appendix 1**). From this streak, further two streaks are made using either the same loop or a 1 μ L loop to ensure growth of single colonies. Incubate the plates at 44°C \pm 0.5°C for 18-22 h.
8. Based on colony morphology (presumptive ESBL-/AmpC producing *E. coli* colonies will usually be red/purple on the MacConkey agar plates containing 1 mg/L cefotaxime – see **Figure 1**), subculture individual colonies onto MacConkey agar containing 1 mg/L cefotaxime to maintain the selective pressure. Up to three colonies should be individually subcultured. Incubate at 37°C \pm 1°C for 18-22 h. Subsequently, select one of these subcultures for species identification (ID). In case the first subculture is not identified as *E. coli*, the second and eventually the third subculture shall be tested.
9. One confirmed *E. coli* isolate presumptively producing ESBL- /AmpC shall be re-subcultured to avoid contamination and to confirm the growth in presence of 1 mg/L cefotaxime. This is performed by picking one single colony from the subculture and streaking it on a new plate of the relevant selective agar, which is then incubated at 37°C \pm 1°C for 18-22 h. This re-subcultured bacterial isolate should be stored under appropriate conditions in your strain collection (e.g. in a -80°C freezer). This set of cultures should serve as reference if discrepancies are detected during the testing (e.g. they can be used to detect errors such as mislabelling or contamination), and they can function as reference material available for reference at a later stage, when needed.



Figure 1: Typical appearance of *E. coli* on MacConkey agar supplemented with 1 mg/L cefotaxime.

The participants are responsible for assuring the validity of the plates by testing a positive (a known ESBL-/AmpC producing *E. coli*) and a negative (ESBL-/AmpC **non**-producing *E. coli*) control. A protocol for ‘Validation of selective MacConkey agar plates supplemented with 1 mg/L cefotaxime for monitoring of ESBL and AmpC producing *E. coli* in meat and animals’ is available on the [EURL-AR webpage](#).



Appendix 1: Matrix EQA 2024 protocol



Appendix 1: Matrix EQA 2024 protocol

3.4 Antimicrobial susceptibility testing

If the sample is considered positive for ESBL- , AmpC- or carbapenemase-producing *E. coli*, one *E. coli* isolate per sample should be taken further and tested for susceptibility towards as many as possible of the antimicrobials listed in **Table 1**, but always considering their relevance regarding the laboratory's routine work. Note that some of the antimicrobials (**highlighted**) could be omitted by the Human Health laboratories. Please use the methods routinely used in your own laboratory.

The reference values used in this Matrix EQA for interpreting MIC and disk diffusion results are in accordance with current zone diameter and MIC breakpoint values developed by CLSI (M100, 34th Ed.). When not available, EUCAST clinical breakpoints (Tables v. 13.1, 2023) or epidemiological cut off values (<https://mic.eucast.org/>) are used instead.

Table 1. Breakpoints for interpretation of MICs and zone diameters for *E. coli*

The highlighted antimicrobials could be omitted by the Human Health laboratories.

Antimicrobials	Reference values			Reference values		
	MIC ($\mu\text{g/mL}$)			Disk diffusion (mm)		
	S	I	R	S	I	R
Amikacin, AMK	≤ 4	8	≥ 16	≥ 20	17-19	≤ 16
Ampicillin, AMP	≤ 8	16	≥ 32	≥ 17	14-16	≤ 13
Azithromycin, AZI	≤ 16	-	≥ 32	≥ 13	-	≤ 12
Cefepime, FEP	≤ 2	4-8	≥ 16	≥ 25	19-24	≤ 18
Cefotaxime, FOT	≤ 1	2	≥ 4	≥ 26	23-25	≤ 22
Cefotaxime + clavulanic acid, F/C	NA	NA	NA	NA	NA	NA
Cefoxitin, FOX	≤ 8	16	≥ 32	≥ 18	15-17	≤ 14
Ceftazidime, TAZ	≤ 4	8	≥ 16	≥ 21	18-20	≤ 17
Ceftazidime + clavulanic acid, T/C	NA	NA	NA	NA	NA	NA
Chloramphenicol, CHL	≤ 8	16	≥ 32	≥ 18	13-17	≤ 12
Ciprofloxacin, CIP	≤ 0.25	0.5	≥ 1	≥ 26	22-25	≤ 21
Colistin, COL	-	≤ 2	≥ 4	NA	NA	NA
Doripenem, DOR	≤ 1	2	≥ 4	≥ 23	20-22	≤ 19
Ertapenem, ETP	≤ 0.5	1	≥ 2	≥ 22	19-21	≤ 18
Gentamicin, GEN	≤ 2	4	≥ 8	≥ 18	15-17	≤ 14
Imipenem, IMI	≤ 1	2	≥ 4	≥ 23	20-22	≤ 19
Levofloxacin, LEVO	≤ 0.5	1	≥ 2	≥ 21	17-20	≤ 16
Meropenem, MERO	≤ 1	2	≥ 4	≥ 23	20-22	≤ 19
Nalidixic acid, NAL	≤ 16	-	≥ 32	≥ 19	14-18	≤ 13
Piperacillin/tazobactam, PT4	$\leq 8/4$	16/4	$\geq 32/4$	≥ 25	21-24	≤ 20
Sulfamethoxazole, SMX	≤ 256	-	≥ 512	≥ 17	13-16	≤ 12
Tetracycline, TET	≤ 4	8	≥ 16	≥ 15	12-14	≤ 11
Tigecycline, TGC*	≤ 0.5	-	≥ 1	≥ 18	-	≤ 17

Tobramycin, TOB	≤ 2	4	≥ 8	≥ 17	13-16	≤ 12
Trimethoprim, TMP	≤ 8	-	≥ 16	≥ 16	11-15	≤ 10
Trimethoprim/sulfamethoxazole, SXT	≤ 2/38	-	≥ 4/76	≥ 16	11-15	≤ 10

Reference values are based on Enterobacterales breakpoints from CLSI M100, 34th Ed.

*Reference values are based on Enterobacterales clinical breakpoints from “The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1, 2023. <http://www.eucast.org>.”

Beta-lactam and carbapenem resistance

The following tests for detection of ESBL-, AmpC-, and carbapenemase-producing phenotypes for *E. coli* are recommended:

- Reduced susceptibility to cefotaxime (FOT) and/or ceftazidime (TAZ): it indicates that the bacterial strain is an ESBL-, AmpC, or carbapenemase-producing phenotype. These strains should be tested for ESBL-, AmpC, or carbapenemase-production by confirmatory tests.
- Confirmatory test for ESBL production: it requires the use of both cefotaxime (FOT) and ceftazidime (TAZ) alone, as well as in combination with a β-lactamase inhibitor (clavulanic acid). Synergy can be determined by broth microdilution methods, Gradient Test or Disk Diffusion:
 - It is defined as a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in combination with clavulanic acid vs. its MIC when tested alone (Gradient Test 3 dilution steps difference; MIC FOT : FOT/Cl or TAZ : TAZ/Cl ratio ≥ 8).
 - A positive synergy testing for Disk Diffusion is defined as ≥ 5 mm increase of diameter of FOT or TAZ in combination with clavulanic acid (FOT/Cl or TAZ/Cl) compared to testing them alone. The presence of synergy indicates ESBL production.
- Detection of AmpC-type beta-lactamases: it can be performed by testing the bacterial culture for susceptibility to ceftoxitin (FOX). Resistance to FOX indicates the presence of an AmpC-type beta-lactamase.
- Confirmatory test for carbapenemase production: it requires the testing of meropenem (MERO). Resistance to MERO indicates that the bacterial strain is a carbapenemase-producer.

It should be noted that some resistance mechanisms do not always confer clinical resistance. Therefore, the classification of the phenotypic results (**Figure 2** below) should be based on the “EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance”, Version 2.0, July 2017, and the most recent EFSA recommendations – The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2017/2018. EFSA Journal 2020;18 (3) <https://doi.org/10.2903/j.efsa.2020.6007>

1. ESBL-Phenotype		
	MIC (mg/L)	Zone Diameter (mm)
FOT or TAZ	> 1	< 21 (FOT); < 22 (TAZ)
MERO	≤ 0.12	≥ 25
FOX	≤ 8	≥ 19
FOT/CLV and/or TAZ/CLV	SYNERGY	SYNERGY

2. AmpC-Phenotype		
	MIC (mg/L)	Zone Diameter (mm)
FOT or TAZ	> 1	< 21 (FOT); < 22 (TAZ)
MERO	≤ 0.12	≥ 25
FOX	> 8	< 19
FOT/CLV and/or TAZ/CLV	NO SYNERGY	NO SYNERGY

3. ESBL + AmpC-Phenotype		
	MIC (mg/L)	Zone Diameter (mm)
FOT or TAZ	> 1	< 21 (FOT); < 22 (TAZ)
MERO	≤ 0.12	≥ 25
FOX	> 8	< 19
FOT/CLV and/or TAZ/CLV	SYNERGY	SYNERGY

4. Carbapenemase-Phenotype		
	MIC (mg/L)	Zone Diameter (mm)
MERO	> 0.12	< 25

5. Other Phenotypes		
	MIC (mg/L)	Zone Diameter (mm)
1)		
FOT or TAZ	> 1	< 21 (FOT); < 22 (TAZ)
MERO	≤ 0.12	≥ 25
FOX	≤ 8	≥ 19
FOT/CLV and/or TAZ/CLV	NO SYNERGY	NO SYNERGY
2)		
FOT or TAZ	≤ 1	≥ 21 (FOT); ≥ 22 (TAZ)
MERO	≤ 0.12	≥ 25
FOX	> 8	< 19

Susceptible		
	MIC (mg/L)	Zone Diameter (mm)
FOT or TAZ	≤ 1	≥ 21 (FOT); ≥ 22 (TAZ)
MERO	≤ 0.12	≥ 25
FOX	≤ 8	≥ 19

Figure 2: Adapted from EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2020 – The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2017/2018 – and in accordance with the EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, Version 2.0, July 2017.

The genotype obtained by PCR and/or sequencing may be necessary to correctly categorize a bacterial test strain as either of the categories, ESBL-, AmpC, and/or carbapenemase-producer, but is NOT requested as part of this Matrix EQA.

Even though this protocol for monitoring ESBL- and AmpC-producing *E. coli* has the potential to detect also most variants of carbapenemases produced in *E. coli*, as these normally confer reduced susceptibility to third-generation cephalosporins, an exception is represented by OXA-48 and OXA-48-like producers, which will be undetected by using the ESBL/AmpC monitoring protocol unless



Appendix 1: Matrix EQA 2024 protocol

they simultaneously co-produce an ESBL or an AmpC enzyme. Therefore, to specifically isolate carbapenemase-producing *E. coli* (including strains producing OXA-48 and OXA-48-like enzymes) from the cultures mimicking meat samples, it may be required to choose selective agar plates that have been validated with regard to specificity and sensitivity of detection of carbapenemase-producing *E. coli*. For example, commercially available chromogenic agar for isolation of carbapenemase-producing *E. coli* (including isolates producing only OXA-48 and/or OXA-48-like enzymes) can be used. A protocol for 'Validation of selective and indicative agar plates for monitoring of carbapenemase-producing *E. coli*' is available on the [EURL-AR webpage](#). We encourage you to perform the validation, but it is optional and NOT requested as part of this EQA.



Appendix 1: Matrix EQA 2024 protocol

4 SUBMISSION OF RESULTS VIA THE INFORMATICS MODULE

We recommend that you write down your results in the enclosed test forms as it will help you when transferring results onto the online platform.

The detailed 'Guideline for reporting results in the EQAsia Informatics Module' is available for download directly from the [EQAsia website](#). Please follow the guideline carefully.

Login to the Informatics Module:

Access the Informatics Module (incognito window) via the following link <https://eqasia-pt.dtu.dk/>

When first given access to login to the Informatics Module, your **personal login ID and password** is sent to you by email.

Note that the primary contact person for a participating institution is registered both as primary and secondary contact. Should you like to add another person as the secondary contact, please contact eqasia@food.dtu.dk

When you submit your results, remember to have by your side the completed test forms (template available for download from the [EQAsia website](#)). If the same reference strain is used for different pathogens, please enter the results (even if the same) for all the pathogens.

Results must be submitted no later than November 25th, 2024.

If you have troubles entering your results or if you experience technical problems with the informatics module, please contact the DTU team directly at eqasia@food.dtu.dk, explaining the issues that you encountered.

Before submitting your final input for all the organisms, please ensure that you have filled in all the relevant fields as **you can only 'finally submit' once!** 'Final submit' blocks further data entry.

After submission, the Informatics Module will allow you to view and print a report with your submitted results.

5 EVALUATION OF RESULTS

The scores for the submitted results will be released after the submission deadline has passed. Then, you will be able to access the evaluation of your results. Results in agreement with the expected interpretation are categorised as ‘4’ (correct), while results deviating from the expected interpretation are categorised as ‘3’ (incorrect, minor), ‘1’ (incorrect, major) or ‘0’ (incorrect, very major).

SCORES		Obtained Interpretation		
		Susceptible	Intermediate	Resistant
Expected Interpretation	Susceptible	4	3	1
	Intermediate	3	4	3
	Resistant	0	3	4

0	Incorrect: very major
1	Incorrect: major
3	Incorrect: minor
4	Correct

Once the results have been evaluated, you will be able to access your certificate via the EQAsia Informatics Module. You will be notified by email when the certificate is available. The certificate will contain score for identification and for susceptibility testing for each of the panels for which you submitted results. Performance rate for each panel will also be shown on the certificate.

The EQAsia project team would like to thank you once again for your participation in this EQA round!

APPENDIX 1

Composition and preparation of culture media and reagents (available on [EURL-AR protocols](#))

The Buffered Peptone Water (BPW), MacConkey agar media and reagents are available from several companies. The composition of the dehydrated media given below is an example and may vary slightly among the different manufacturers. Of note, the media should be prepared according to the manufacturer's instructions, if they differ from the description given here.

Buffered peptone water (Example)

<i>Formula</i>	<i>g/L</i>
Enzymatic digest of casein	10.0
Sodium chloride	5.0
Disodium hydrogen phosphate dodecahydrate ($\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$)	9.0
Potassium dihydrogen phosphate (KH_2PO_4)	1.5
pH 7.0 +/- 0.2 @ 25°C	

Dissolve the components in water by heating if necessary. Adjust the pH so that after sterilization it is 7.0 +/- 0.2 at 25°C. Dispense the medium into flasks of suitable capacity to obtain the portions necessary for the test. Sterilize by autoclaving at 121°C for 15 minutes.

MacConkey agar (Example)

<i>Formula</i>	<i>g/L</i>
Pancreatic Digest of Gelatin	17.0
Peptones (meat and casein)	3.0
Lactose	10.0
Bile salts No. 3	1.5
Sodium chloride	5.0
Neutral red	0.03
Crystal violet	0.001
Agar	13.5
pH 7.1 +/- 0.2 @ 25°C	

Suspend 50 g in 1 L of distilled water (Optional: Add 6.5 g agar to increase the hardness of the agar plates). Bring to the boil to dissolve completely. Sterilize by autoclaving at 121°C for 15 minutes.

Selective Supplements

<i>Formula</i>	<i>mg/mL</i>
Cefotaxime sodium salt stock solution prepared in bi-distilled water	1

It is important to take into account the potency of the drug to ensure that 1 mg/mL active compound is used. Aliquots of aqueous cefotaxime stock solution (concentration 1 mg/mL) can be stored at -20°C.

Example: If the manufacturer has stated a potency of 50%, 2 mg of antibiotic powder should be added to 1 mL of sterile dH₂O (or the solvent routinely used) to reach a final concentration of 1 mg/mL of active compound.

Appendix 2: Reference values (MIC) – *Escherichia coli*

The 4th EQAsia Matrix EQA on selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing *Escherichia coli* from cultures mimicking meat samples – 2024

Reference values (MIC values and interpretation) – *Escherichia coli*

	Amikacin AMK		Ampicillin AMP		Azithromycin AZI		Cefepime FEP		Cefotaxime FOT		FOT+CI F/C		Cefoxitin FOX		Ceftazidime TAZ		TAZ+CI T/C	
EQAsia 24.M1	≤4	S	>32	R	64	R	16	R	>32	R	≤ 0.06	4	S	1	S	≤0.12		
EQAsia 24.M2	≤4	S	>32	R	>64	R	16	R	>32	R	≤ 0.06	16	I	16	R	0.25		
EQAsia 24.M3	≤4	S	>32	R	64	R	16	R	>32	R	>64	>64	R	>128	R	>128		
EQAsia 24.M4	≤4	S	>32	R	4	S	0.25	S	16	R	8	64	R	16	R	8		

R, Resistant; I, Intermediate; S, Susceptible

	Chloramphenicol CHL		Ciprofloxacin CIP		Colistin COL		Doripenem DOR		Ertapenem ETP		Gentamicin GEN		Imipenem IMI		Levofloxacin LEVO		Meropenem MERO	
EQAsia 24.M1	>64	R	0.12	S	≤0.25	I	≤0.12	S	≤0.25	S	≤1	S	≤1	S	≤1	S/I	≤0.03	S
EQAsia 24.M2	64	R	>8	R	>4	R	≤0.12	S	≤0.25	S	≤1	S	≤1	S	>8	R	≤0.03	S
EQAsia 24.M3	≤8	S	>8	R	≤0.25	I	>2	R	>4	R	≤1	S	4	R	>8	R	8	R
EQAsia 24.M4	≤8	S	≤0.015	S	4	R	≤0.12	S	≤0.25	S	≤1	S	≤1	S	≤1	S/I	≤0.03	S

R, Resistant; I, Intermediate; S, Susceptible

The 4th EQAsia Matrix EQA on selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing *Escherichia coli* from cultures mimicking meat samples – 2024

	Nalidixic acid NAL		Piperacillin/ tazobactam P/T4		Sulfamethoxazole SMX		Tetracycline TET		Tigecycline TGC		Tobramycin TOB		Trimethoprim TMP		Trimethoprim/ sulfamethoxazole SXT	
	≤4	S	≤8	S	>512	R	>32	R	≤0.25	S	≤1	S	>16	R	>4	R
EQAsia 24.M1	≤4	S	≤8	S	>512	R	>32	R	≤0.25	S	≤1	S	>16	R	>4	R
EQAsia 24.M2	>64	R	≤8	S	>512	R	>32	R	≤0.25	S	≤1	S	>16	R	>4	R
EQAsia 24.M3	>64	R	>64	R	>512	R	>32	R	≤0.25	S	≤1	S	>16	R	>4	R
EQAsia 24.M4	≤4	S	≤8	S	≤8	S	>32	R	≤0.25	S	≤1	S	≤0.25	S	≤0.5	S

R, Resistant; I, Intermediate; S, Susceptible

Appendix 3: Quality control ranges for reference strains

<i>E. coli</i> ATCC 25922		
Antimicrobial	MIC (mg/L)	Inhibition Zone Diameter (mm)
Amikacin, AMK	0.5-4	19-26
Ampicillin, AMP	2-8	15-22
Azithromycin, AZI	--	--
Cefepime, FEP	0.016-0.12	31-37
Cefotaxime, FOT	0.03-0.12	29-35
Cefotaxime and clavulanic acid, F/C	--	--
Cefoxitin, FOX	2-8	23-29
Ceftazidime, TAZ	0.06-0.5	25-32
Ceftazidime and clavulanic acid, T/C	--	--
Chloramphenicol, CHL	2-8	21-27
Ciprofloxacin, CIP	0.004-0.016	29-38
Doripenem, DOR	0.016-0.06	27-35
Ertapenem, ETP	0.004-0.016	29-36
Gentamicin, GEN	0.25-1	19-26
Imipenem, IMI	0.06-0.5	26-32
Levofloxacin, LEVO	0.008-0.06	29-37
Meropenem, MERO	0.008-0.06	28-35
Nalidixic acid, NAL	1-4	22-28
Piperacillin and tazobactam, P/T4	1-4	24-30
Sulfamethoxazole, SMX	8-32	15-23
Tetracycline, TET	0.5-2	18-25
Tigecycline, TGC	0.03-0.25	20-27
Tobramycin, TOB	0.25-1	18-26
Trimethoprim, TMP	0.5-2	21-28
Trimethoprim and sulfamethoxazole, SXT	≤ 0.5	23-29

MIC ranges and disk diffusion ranges are according to CLSI M100 34th edition, Tables 4A-1 and 5A-1

<i>E. coli</i> NCTC 13846		
Antimicrobial	MIC (mg/L)	Inhibition Zone Diameter (mm)
Colistin, COL	2-8	--

MIC range in accordance to "The European Committee on Antimicrobial Susceptibility Testing. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. [Version 12.0, 2022.](http://www.eucast.org) [http://www.eucast.org.](http://www.eucast.org)"



DTU Fødevareinstituttet
DTU National Food Institute

Henrik Dams Allé
2800 Kgs. Lyngby

+45 35 88 70 00

food.dtu.dk